How many clinical trials are studying Apalutamide (Erleada™) 60 mg or 240 mg tablets?

3 recruiting trials in our tracked data involve Apalutamide (Erleada™) 60 mg or 240 mg tablets.

What conditions is Apalutamide (Erleada™) 60 mg or 240 mg tablets being studied for?

In our tracked recruiting trials, Apalutamide (Erleada™) 60 mg or 240 mg tablets is being studied in trials for Prostate Cancer, Castrate Sensitive Prostate Cancer, Metastatic Cancer.

Apalutamide (Erleada™) 60 mg or 240 mg tablets: clinical trials recruiting now

Recruiting trials

Conditions studied

US states with sites

Countries

Phase breakdown

Phase 1 1 Phase 3 1 Not applicable 1

Conditions being studied

Condition	Trials
Prostate Cancer · Apalutamide (Erleada™) 60 mg or 240 mg tablets for Prostate Cancer	3
Castrate Sensitive Prostate Cancer	1
Metastatic Cancer	1
Metastatic Hormone-sensitive Prostate Cancer	1
Metastatic Prostate Cancer	1

Recruiting trials involving Apalutamide (Erleada™) 60 mg or 240 mg tablets

PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
NCT06652607 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · 1 location
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
NCT07333066 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 56 locations
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
NCT05413421 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 27 locations

Common questions

How many recruiting trials involve Apalutamide (Erleada™) 60 mg or 240 mg tablets?

3 recruiting trials across 5 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.